At MyOme, we are dedicated to transforming cancer diagnostics through advanced tissue mapping technology. Founded in 2018 and headquartered in Waltham, Massachusetts, we specialize in providing spatial proteomics solutions to enhance cancer detection and enable precision medicine.

Our innovative platform allows researchers and clinicians to analyze tumor microenvironments with unprecedented detail. By precisely mapping proteins within tissue samples, we help identify critical biomarkers and cellular interactions that inform personalized treatment strategies. This approach enables more accurate diagnosis and better patient outcomes.

We believe that the future of oncology lies in spatial biology. Our technology integrates seamlessly with current pathology workflows, providing comprehensive insights without compromising existing processes. Our team comprises experts in biotechnology, engineering, and computational analysis, all committed to pushing the boundaries of cancer research.

MyOme continually strives to support researchers and healthcare providers by offering cutting-edge tools that facilitate discovery and clinical translation. Our commitment to quality, accuracy, and innovation drives us to deliver reliable and meaningful data to our partners worldwide.

As a company focused on actionable insights, we partner closely with cancer centers, pharmaceutical companies, and academic institutions. Together, we aim to accelerate the development of targeted therapies and improve patient care through enhanced understanding of tumor biology.